Table 2.
Demographic and prescription data of response cohort by CYP2C19 phenotype.
| Parameter | Total n = 180 | PM n = 4 (2%) | IM n = 41 (23%) | NM n = 77 (43%) | RM n = 48 (26%) | UM n = 10 (6%) |
|---|---|---|---|---|---|---|
| Age (years) Average (range) | 14.8 (6.8–18.6) | 13.5 (12.1–15.2) | 14.9 (6.8–17.5) | 14.8 (9.7–18.6) | 14.6 (9.4–18.6) | 15.2 (12.0–17.4) |
| <12 (n, %) | 18 (10%) | – | 5 (12%) | 7 (9%) | 6 (13%) | – |
| ≥12 (n, %) | 162 (90%) | 4 (100%) | 36 (88%) | 70 (91%) | 42 (87%) | 10 (100%) |
| Diagnosis | ||||||
| Anxiety (n, %) | 22 (12%) | 1 (25%) | 5 (12%) | 10 (13%) | 6 (12%) | – |
| Depressive (n, %) | 44 (25%) | 0 | 12 (29%) | 20 (26%) | 9 (19%) | 3 (30%) |
| Anxiety+Depressive (n, %) | 114 (63%) | 3 (75%) | 24 (59%) | 47 (61%) | 33 (69%) | 7 (70%) |
| Sex | ||||||
| Female (n, %) | 119 (66%) | 2 (50%) | 29 (71%) | 49 (64%) | 33 (69%) | 6 (60%) |
| Male (n, %) | 61 (34%) | 2 (50%) | 12 (29%) | 28 (36%) | 15 (31%) | 4 (40%) |
| Race | ||||||
| Black (n, %) | 16 (9%) | 0 | 5 (12%) | 5 (7%) | 4 (8%) | 2 (20%) |
| Other (n, %) | 18 (10%) | 1 (25%) | 6 (15%) | 8 (10%) | 3 (6%) | – |
| White (n, %) | 146 (81%) | 3 (75%) | 30 (73%) | 64 (83%) | 41 (86%) | 8 (80%) |
| Es/citalopram prescriptions n (%) | ||||||
| Only escitalopram | 147 (82%) | 3 (75%) | 46 (88%) | 60 (78%) | 39 (81%) | 9 (90%) |
| Only citalopram | 24 (13%) | 1 (25%) | 3 (7%) | 12 (16%) | 7 (15%) | 1 (10%) |
| Both | 9 (5%) | 0 | 2 (5%) | 5 (6%) | 2 (4%) | 0 |
| Total time on es/citalopram (days) Median (range) | 290.5 (28–1974) | 112 (35–293) | 284 (30–1974) | 328 (31–1424) | 290 (28–1206) | 188 (32–1129) |
| Response n (%) | 117 (65%) | 1 (25%) | 23 (56%) | 49 (64%) | 37 (77%) | 7 (70%) |
| # of concomitant medications Median (range) | 2 (0–9) | 1.5 (1–4) | 2 (0–9) | 2 (0–8) | 2 (0–6) | 2 (0–4) |
| Concomitant omeprazole n (%) | 17 (9%) | 0 (0%) | 4 (10%) | 6 (8%) | 4 (8%) | 3 (30%) |
| Concomitant oral contraceptives n (%) | 19 (11%) | 0 (0%) | 6 (15%) | 9 (12%) | 3 (6%) | 1 (10%) |
| Maximum dose (mg) Median (range) | 20 (2.5–40) | 12.5 (5–20) | 15 (2.5–40) | 20 (5–40) | 15 (5–30) | 20 (10–20) |
n, number; mg, milligrams; PM, poor metabolizer; IM, intermediate metabolizer; NM, normal metabolizer; RM, rapid metabolizer; UM, ultrarapid metabolizer.